CG Oncology, Inc. (CGON)

NMS – Цена в реальном времени. Валюта: USD

71.96

-0.88 (-1.21%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

71.96

-0.00 (-0.00%)

После закрытия: Jun 26, 2026, 4:34 PM EDT

10.06.2026

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.

09.06.2026

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

07.06.2026

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer, Chief Executive Officer Arthur Kuan said during a discussion at the Jefferies Global Healthcare Conference in New York.

28.05.2026

CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference this month. The details of the upcoming events are as follows:

21.05.2026

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company's investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones.

19.05.2026

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year's awardees recently presented their research at the SUO 2026 Annual Meeting at the AUA SCHAUMBURG, Ill. and DALLAS, May 19, 2026 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the recipients of the second annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

15.05.2026

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively

Видео

No Data

There is no data to display

Пресс-релизы

19.05.2026

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

15.05.2026

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively

11.05.2026

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

08.05.2026

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.

CG Oncology, Inc. (CGON)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CG Oncology, Inc. (CGON)

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

Видео

No Data

Пресс-релизы

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

Видео

No Data

Пресс-релизы

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Search stocks

CG Oncology, Inc. (CGON)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CG Oncology, Inc. (CGON)

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

Видео

No Data

Пресс-релизы

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead

CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push

CG Oncology to Present at Upcoming Investor Conferences in June

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

Видео

No Data

Пресс-релизы

SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

CG Oncology's Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates